therapie-online.de – Date: 17.05.2024
Author: therapie-online.de – Source
Novogenia is revolutionising Germany’s healthcare sector by replacing traditional treatment methods with personalised health strategies based on genetic analysis. Dr. Daniel Wallerstorfer, CEO of Novogenia, highlights the significance of this personalised approach, which tailors patient care to individual genetic profiles. Founded in 2009, Novogenia leads in genetic research, offering preventive lifestyle analyses and personalised supplements. Dr. Wallerstorfer advocates for a shift towards personalised medicine in Germany, emphasising the potential of genetic analysis to enhance healthcare outcomes and cater to the unique biological needs of each individual.
